KRAS and lung carcinoma: In line with PRC2 function being anti-tumor, deletion of the PRC2 component Eed enhanced malignancy in KRAS+/Trp53-null lung cancers, drove aggressive mucinous tumors, and changed the tumor immune microenvironment10,11.